Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether TCR2 Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as TCR2 Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
TCR2 Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
TCR2 Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
TCR2 Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
Examine TCR2 Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through TCR2 Therapeutics's regulatory filings and announcements.
TCR2 Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if TCR2 Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
TCR2 Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
TCR2 Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
TCR2 Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
TCR2 Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
TCR2 Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
TCR2 Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Garry E. Menzel, Ph.D. serves as President, Chief Executive Officer and Director of TCR2, Inc. Dr. Menzel served as the Chief Strategy and Financial Officer of Axcella Health, Inc. Dr. Menzel served as Chief Business and Strategy Officer at Axcella Health, Inc. since October 19, 2015. Dr. Menzel served as the Chief Financial Officer of DaVita HealthCare Partners Inc. from September 30, 2013 to March 2015. Dr. Menze served as Senior Vice President of Finance at DaVita HealthCare Partners Inc. from September 16, 2013 to September 30, 2013. He served as the Chief Operating Officer and Executive Vice President of Finance at Regulus Therapeutics Inc. (Regulus Therapeutics, LLC) from January 2009 to June 21, 2013. Dr. Menzel served as the Chief Financial Officer of Regulus Therapeutics Inc. Dr. Menzel served as an Executive Vice President of Corporate Development & Finance of Regulus Therapeutics LLC from August 2008 to January 2009. Dr. Menzel served as Senior Vice President and Head of Global Biotechnology Investment Banking of Goldman Sachs, which he joined in 1994. He led the IPO and significant strategic partnerships with Astra Zeneca, GlaxoSmithKline and Sanofi. He served as Global Head of Life Sciences for Credit Suisse. Dr. Menzel served as Consultant of Bain & Company. He served as the Managing Director and Founding Member of the Healthcare Group. Dr. Menzel was employed by Credit Suisse (USA), Inc. and The Goldman Sachs Group, Inc. Dr. Menzel joined Credit Suisse in 2004 and served as its Managing Director. He served a broad range of biotechnology and pharmaceutical clients around the world, raising capital and negotiating merger agreements for some of its most significant transactions. He serves as Director Emeriti of the Institute for Systems Biology. Dr. Menzel serves as an Executive Board Member of the Epilepsy Therapy Project. He served as a Director of Endeavor Pharmaceuticals Inc., since 2001. He is Associate of the Royal College of Science. Dr. Menzel earned a B.Sc. with honors in Biochemistry from Imperial College of Science & Technology in 1985, a Ph.D. in Molecular Biology from the University of Cambridge in 1988 and an M.B.A. from the Stanford Graduate School of Business in 1994.
Garry's compensation has increased whilst company is loss making.
Garry's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the TCR2 Therapeutics management team is about average.
Chief Scientific Officer
Chief Medical Officer
Chief Financial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the TCR2 Therapeutics board of directors is about average.
Board of Directors
Chairman of the Board of Directors
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by TCR2 Therapeutics insiders in the past 3 months.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.